Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D9NZ
|
|||
| Former ID |
DNC000934
|
|||
| Drug Name |
Methoxyestradiol
|
|||
| Synonyms |
SCHEMBL18733359; CHEMBL1473145; HMS3229K11
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H26O3
|
|||
| Canonical SMILES |
CC12CCC3C(C1CCC2O)CCC4=C3C(=CC(=C4)O)OC
|
|||
| InChI |
1S/C19H26O3/c1-19-8-7-14-13(15(19)5-6-17(19)21)4-3-11-9-12(20)10-16(22-2)18(11)14/h9-10,13-15,17,20-21H,3-8H2,1-2H3/t13-,14-,15-,17-,19-/m0/s1
|
|||
| InChIKey |
PJCUYTOXKIUJSL-SARNLOFESA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Superoxide dismutase Cu-Zn (SOD Cu-Zn) | Target Info | Inhibitor | [1] |
| BioCyc | Reactive oxygen species degradation | |||
| KEGG Pathway | Peroxisome | |||
| Amyotrophic lateral sclerosis (ALS) | ||||
| Huntington's disease | ||||
| Prion diseases | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Pathwhiz Pathway | Degradation of Superoxides | |||
| Pathway Interaction Database | Validated nuclear estrogen receptor alpha network | |||
| FOXA1 transcription factor network | ||||
| Reactome | Platelet degranulation | |||
| Detoxification of Reactive Oxygen Species | ||||
| WikiPathways | Oxidative Stress | |||
| Copper homeostasis | ||||
| Detoxification of Reactive Oxygen Species | ||||
| Nifedipine Activity | ||||
| Amyotrophic lateral sclerosis (ALS) | ||||
| Dopamine metabolism | ||||
| AGE/RAGE pathway | ||||
| Folate Metabolism | ||||
| Vitamin B12 Metabolism | ||||
| Selenium Micronutrient Network | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol. A superoxide dismutase inhibitor. J Biol Chem. 2003 Jan 3;278(1):407-14. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.